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Abstract Cellular and molecular mechanisms involved in the
resistance to cytotoxic heavy metals remain largely to be
characterized in mammalian cells. To this end, we have analyzed
a metal-resistant variant of the human lung cancer GLC4 cell
line that we have selected by a step-wise procedure in potassium
antimony tartrate. Antimony-selected cells, termed GLC4/Sb30
cells, poorly accumulated antimony through an enhanced cellular
efflux of metal, thus suggesting up-regulation of a membrane
export system in these cells. Indeed, GLC4/Sb30 cells were found
to display a functional overexpression of the multidrug
resistance-associated protein MRP1, a drug export pump, as
demonstrated by Western blotting, reverse transcriptase-
polymerase chain reaction and calcein accumulation assays.
Moreover, MK571, a potent inhibitor of MRP1 activity, was
found to markedly down-modulate resistance of GLC4/Sb30
cells to antimony and to decrease cellular export of the metal.
Taken together, our data support the conclusion that over-
expression of functional MRP1 likely represents one major
mechanism by which human cells can escape the cytotoxic effects
of heavy metals.
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1. Introduction
Most heavy metals are devoid of physiological functions
and are potentially toxic for prokaryotes and eukaryotes.
Thus, arsenic, cadmium and antimony have been shown to
be highly toxic toward cultured cells and are presumed to
be genotoxic and/or carcinogenic agents in humans [1]. Their
cytotoxic e¡ects can, however, be reduced in heavy metal-se-
lected cells but the cellular mechanisms involved are not fully
understood. A major one is related to overexpression of low
molecular weight cysteine-rich proteins known as metallothio-
neins (MT), which bind heavy metals such as cadmium, there-
by preventing them from reaching their intracellular targets
[1]. Another mechanism is linked to decreased metal intracel-
lular accumulation and reduced levels of arsenic or antimony
have been demonstrated in di¡erent resistant cell lines [2^4].
Low accumulation of metal could result from either a de-
creased cellular in£ux or an increased cellular e¥ux. It may
be linked to cellular glutathione content [4] and is most likely
related to an altered expression of membrane systems of metal
transport ; however, the transporters involved remain largely
unknown in mammalian cell lines. For e¥ux processes, it can
been hypothesized that they may be members of the ATP-
binding cassette (ABC) transporter superfamily that contains
several detoxifying pumps such as P-glycoprotein (P-gp),
multidrug resistance-associated protein 1 (MRP1) and canal-
icular multispeci¢c organic anion transporter (cMOAT) [5].
Indeed, ABC membrane proteins such as Leishmania LtpgpA
and yeast cadmium resistance facor 1 (YCF1) have already
been incriminated in heavy metal resistance in unicellular eu-
karyotic organisms [6,7]. Moreover, transfection experiments
of the cDNA encoding human MRP1 into human tumor cells
have recently demonstrated that this e¥ux pump, in addition
to mediating outwardly directed transport of anticancer drugs
[8,9], may also interact with genotoxic heavy metals such as
arsenite and antimony [8]. In order to improve knowledge of
the detoxifying pathways displayed by heavy metal-selected
human cells, in particular with respect to carrier-mediated
membrane transport of metals, we have generated and ana-
lyzed a human antimony-selected lung cancer cell line. Our
results demonstrate that these antimony-selected cells, which
were also cross-resistant to arsenic, displayed enhanced e¥ux
of antimony and overexpressed MRP1.
2. Materials and methods
2.1. Cell culture
An antimony-resistant variant of the human small cell lung cancer
cell line GCL4, kindly provided by Dr. E.G.E. de Vries (University
Hospital Groningen, Groningen, The Netherlands), was generated by
chronic exposure of GLC4 cells to potassium antimony tartrate
(Sb(III)) during which the salt metal concentration was increased
step-wise from 2 to 92 WM over an 8-month period. Antimony-se-
lected GLC4 cells, named GLC4/Sb30, were then routinely main-
tained in the presence of 92 WM Sb(III) until 3 days before experi-
ments. The culture medium used for both GLC4 cells and GLC4/Sb30
cells was RPMI medium supplemented with 10% fetal calf serum and
2 mM glutamine.
2.2. Drug sensitivity
Cytotoxic e¡ects of metals and anticancer drugs were analyzed us-
ing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) colorimetric assay, as previously described [10]. IC50 values
were de¢ned as the mean concentrations reducing absorbance by 50%.
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2.3. Antimony accumulation and e¥ux
Cellular antimony contents were determined after both incubation
of cells with 100 WM Sb(III) for 2^6 h (accumulation studies) and re-
incubation of Sb(III)-loaded cells in Sb(III)-free RPMI medium for up
to 3 h (e¥ux studies) in the absence or presence of 50 WM MK571, a
leukotriene D4 receptor antagonist [11], kindly provided by Dr. Ford-
Hutchinson (Merck-Front Inc., Quebec, Que., Canada), which is
known to inhibit MRP1 activity [12]. Cellular antimony contents
were quanti¢ed using a Zeeman atomic absorption spectrometer
(Spectra A300, Varian, Victoria, Australia) and normalized to cellular
protein content, using the Bio-Rad protein assay [13].
2.4. Western blotting
Proteins were analyzed either on whole cell lysates (for MT) or on
crude membrane protein extracts prepared according to Germann et
al. [14] (for P-gp and MRP1). Proteins were separated on a 7.5% SDS-
polyacrylamide gel and electrotransferred to a nitrocellulose mem-
brane (Amersham, Les Ulis, France) for 24 h at 4‡C. Nitrocellulose
membranes were blocked with 1% skim milk, 1% bovine serum albu-
min and 0.1% Tween-20 Tris bu¡er, and sequentially incubated with
speci¢c monoclonal antibodies raised against MRP1 (MRPm6,
Monosan, Uden, The Netherlands; dilution 1/250), P-gp (C219, Cen-
tocor, Malvern, USA, dilution 1/200) or MT (Dako-MT, E9, Dako,
Carpinteria, USA, dilution 1/200) and then with horseradish perox-
idase-conjugated goat anti-mouse or anti-rabbit IgG (1/2500 dilution).
Immunoreactive proteins were detected using a chemiluminescent sys-
tem (ECL, Amersham, UK).
2.5. RT-PCR experiments
Total cellular RNA was extracted from cells by the guanidinium
thiocyanate/cesium chloride method [15] and mRNA levels were ana-
lyzed by RT-PCR as previously reported [10]. The primers used for
MRP1 and L-actin detection were exactly as previously described
[10,16]. The primers used for cMOAT analysis were: cMOAT sense
primer, 5P-CTAGCAGCCATAGAGCTGGC-3P ; cMOAT antisense
primer, 5P-TGGCTCCAGAGTTCTGCTGG-3P.
2.6. Southern blotting
Genomic DNA (20 Wg) was digested with EcoRI, electrophoresed
through a 0.8% agarose gel and transferred onto Hybond-N mem-
brane (Amersham). Membranes were prehybridized for at least 3 h at
65‡C, hybridized with a 32P-labelled 0.4 kb MRP1 cDNA probe for 18
h at 65‡C and then autoradiographed at 380‡C for 24 h. The MRP1
gene probe was generated by RT-PCR and was identical to MRP1
gene sequences previously described [17,18].
2.7. MRP1 activity
MRP1 activity was assessed by determination of intracellular accu-
mulation of the £uorescent anionic dye calcein, as previously de-
scribed [19]. Cells were loaded with 0.5 WM calcein AM for 1 h at
37‡C without or with probenecid, a modulator of MRP1 [19]. Cellular
calcein contents were then quanti¢ed by £uorimetry, using a Titertek
Fluoroscan spectro£uorometer (Flow Laboratories, Puteaux, France);
excitation and emission wavelengths were 488 nm and 538 nm, re-
spectively.
2.8. Statistical analysis
Results were analyzed by Student’s t-test and the criterion of sig-
ni¢cance of the di¡erences between means ( þ S.E.M.) was P6 0.05.
3. Results
3.1. Resistance pattern of GLC4Sb/30 cells
GLC4/Sb30 cells, generated by a step-wise selection in
Sb(III), were ¢rst examined for their sensitivity to cytotoxic
agents using the MTT assay. Antimony IC50 values were
3.2 þ 0.3 WM and 112.6 þ 11.0 WM for GLC4 cells and
GLC4/Sb30 cells, respectively, demonstrating that GLC4/
Sb30 cells were 35-fold more resistant to Sb(III) when com-
pared to their parental counterparts. Table 1 indicates that
GLC4/Sb30 cells were highly cross-resistant to the pentavalent
antimonial salt meglumine and to the trivalent arsenical salt
arsenite. By contrast, these cells were only slightly resistant, if
at all, to cadmium chloride and zinc sulfate. Antimony-se-
lected cells were also found to be cross-resistant to the two
chemotherapeutic drugs doxorubicin and vincristine.
3.2. Cellular accumulation and e¥ux of antimony
Cellular accumulation of antimony was determined in
GLC4 and GLC4/Sb30 cells exposed to 100 WM Sb(III) for
various lengths of time by atomic absorption spectrometry.
Antimony contents of GLC4/Sb30 cells, which reached a
steady state within the ¢rst 2 h of incubation, were lower
than those measured in GLC4 cells whatever the duration
of exposure to antimony (Fig. 1A). They represented about
60% of the values measured in GLC4 cells after a 6 h incu-
bation with the metal. E¥ux studies were then performed in
order to determine whether impairment of antimony accumu-
lation in GLC4/Sb30 cells was due to enhanced metal cellular
export. Results indicated that the antimony-selected cells
poorly retained antimony after either a 1 h or a 3 h e¥ux
period when compared to parental sensitive cells (Fig. 1B).
3.3. Expression of detoxifying proteins
Western blot analysis failed to detect either MT or P-gp in
both GLC4 and GLC4/Sb30 cells whereas high levels of MT
and P-gp were evidenced in cadmium-treated GLC4 cells and
P-gp-overexpressing drug-resistant K562R/7 cells, respectively
(data not shown). In contrast, immunoblotting with the
monoclonal antibody MRPm6 revealed overexpression of a
MRP1-related 190 kDa protein in GLC4/Sb30 cells when
compared to the parental cells (Fig. 2A). RT-PCR experi-
ments also revealed enhanced levels of MRP1 mRNAs in
GLC4/Sb30 cells compared to GLC4 cells whereas similar
amounts of L-actin mRNAs were evidenced in both sensitive
and resistant cells (Fig. 2B). In contrast, mRNAs of cMOAT,
an ABC membrane transporter sharing numerous substrates
with MRP1 [5], were not detected in either GLC4 cells or
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Table 1
Cross-resistance of GLC4/Sb30 cells to heavy metals and chemotherapeutic drugs
IC50a Resistance factorb P
GLC4 GLC4/Sb30
Meglumine antimonate 1170 þ 0.3 32 170 þ 8.5 27.5 0.001
Sodium arsenite 1.6 þ 0.2 16.1 þ 3.5 10.0 0.006
Cadmium chloride 11.5 þ 2.2 25.9 þ 4.2 2.2 0.013
Zinc sulfate 128.7 þ 21.3 172.8 þ 24.2 1.3 0.22
Vincristine 0.43 þ 0.1c 3.34 þ 0.6c 7.7 0.004
Doxorubicin 10.1 þ 1.2c 51.8 þ 5.6c 5.1 0.03
aThe IC50s were determined using a MTT assay and are expressed as WM concentrations, unless otherwise indicated. Data are the mean þ S.E.M. of
at least three independent experiments. Statistical signi¢cance (P) was determined by Student’s t-test.
bThe resistance factors were calculated by dividing the IC50 values of GLC4/Sb30 cells by those of GLC4 cells.
cnM.
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GLC4/Sb30 cells, but were markedly visualized in human hep-
atocytes used as positive control cells (data not shown). Ge-
nomic DNAs extracted from GLC4 and GLC4/Sb30 cells
were further subjected to Southern blotting and hybridized
with a MRP1 cDNA probe (Fig. 2C). Results showed in-
creased levels of MRP1-related DNA in GLC4/Sb30 cells.
Finally, MRP1 activity was examined using a calcein accumu-
lation assay (Fig. 3). Cellular levels of the £uorescent dye were
found to be strongly decreased in GLC4/Sb30 cells in compar-
ison to those observed in GLC4 cells. However, probenecid, a
well-known inhibitor of MRP1-mediated transport [19], was
able to markedly enhance calcein accumulation in the anti-
mony-resistant cells without altering dye levels in the parental
GLC4 cells (Fig. 3).
3.4. E¡ect of MK571
In order to determine whether MRP1 activity was involved
in the resistance of GLC4/Sb30 cells to Sb(III) cytotoxicity,
the e¡ects of the MRP1 inhibitor MK571 on both metal sen-
sitivity and metal e¥ux were studied using MTT assays and
atomic absorption spectrometry measurements, respectively.
As indicated in Table 2, MK571, used at the non-cytotoxic
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Fig. 2. Analysis of MRP1 expression in GLC4/Sb30 cells. A: MRP1
protein levels. Crude membrane proteins (25 Wg) were prepared and
analyzed by Western blotting using the speci¢c MRP1 monoclonal
antibody MRPm6. Position of molecular weight standard is indi-
cated on the right. B: MRP1 mRNA levels. Total RNAs were pre-
pared and analyzed by RT-PCR using MRP1- and L-actin-speci¢c
primers. C: MRP1 DNA analysis. Genomic DNA (20 Wg) was di-
gested with EcoRI and electrophoresed through a 0.8% agarose gel.
The blot was hybridized with a cDNA-speci¢c fragment of MRP1
and autoradiographed for 24 h at 380‡C. Position of DNA molecu-
lar fragment standards is indicated on the right.
Fig. 1. Accumulation (A) and e¥ux (B) of antimony in GLC4/Sb30
cells. A: GLC4 cells and GLC4/Sb30 cells were incubated with 100
WM Sb(III) and intracellular antimony content was measured at dif-
ferent time intervals and normalized to cellular protein content. B:
GLC4 cells and GLC4/Sb30 cells were ¢rst pre-incubated with 200
WM Sb(III) for 1 h, washed and then incubated in Sb(III)-free me-
dium. Intracellular antimony content was measured at di¡erent time
intervals and expressed as the percentage of initial intracellular anti-
mony accumulation. Each point is the mean þ S.E.M. of at least
three independent experiments performed in duplicate. GLC4 cells
(a), GLC4/Sb30 cells (F). *P6 0.05.
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concentration of 50 WM, almost fully reversed the resistance
of GLC4/Sb30 cells to Sb(III) while it only marginally in-
creased metal sensitivity of the parental cells. In addition,
e¥ux experiments showed that MK571 greatly enhanced cel-
lular retention of antimony in GLC4/Sb30 cells, allowing it to
reach the levels observed in sensitive GLC4 cells. Indeed, after
a 3 h e¥ux period, the amounts of antimony retained in
GLC4/Sb30 cells, MK571-treated GLC4/Sb30 cells and paren-
tal GLC4 cells corresponded to 25.3 þ 6.2, 65.1 þ 13.4 and
53.3 þ 4.5% of the initial cell-associated antimony value, re-
spectively.
4. Discussion
Detoxifying pathways displayed by human heavy metal-se-
lected cells remain largely to be characterized. In this study,
we have established a human lung cancer cell line highly re-
sistant to both trivalent and pentavalent antimonial and tri-
valent arsenical salts by an 8 month exposure to Sb(III). Anal-
ysis of these antimony-selected cells demonstrates that they
did not express metal-detoxifying MT and showed low resist-
ance, if at all, to known MT-interacting metals such as cad-
mium and zinc; in contrast, they displayed reduced levels of
cellular antimony due to enhanced cellular e¥ux of the metal.
Taken together, these data indicate that decreased metal re-
tention is likely a mechanism contributing to the resistance of
GLC4/Sb30 cells. Impairment of metal cellular accumulation
has already been reported in some protozoa [2] and mamma-
lian heavy metal-selected cells [3,4] and therefore appears to
correspond to a common detoxifying pathway displayed by
metal-resistant cells. It should, however, be kept in mind that
such a mechanism of resistance may involve, besides increased
cellular e¥ux, decreased cellular uptake of metals. Indeed, in
contrast to our GLC4/Sb30 cells, antimony-selected 2008/H
ovarian cells have been shown to display metal accumulation
defect without change in metal e¥ux rates [3]. This suggests
that alterations of di¡erent membrane transport systems of
metals can occur in resistant cells according to their origin
or the protocol used for their selection.
Overexpression of the e¥ux pump MRP1, initially demon-
strated in tumor cells selected by anticancer drugs [20,21], was
also observed in GLC4/Sb30 cells at both protein and mRNA
levels. In contrast, antimony-selected cells failed to express
other detoxifying ABC membrane transporters such as P-gp
or cMOAT. Direct and indirect arguments are in favor of a
major role for MRP1 in resistance to heavy metals in GLC4/
Sb30 cells: (i) these antimony-selected cells displayed a pattern
of cross-resistance to heavy metals similar to that found in
human cells transfected with a MRP1 cDNA [8], thereby sug-
gesting that selected cells and transfected cells shared the same
mechanism of resistance; (ii) MRP1 appeared to be fully func-
tional in GLC4/Sb30 cells since these cells showed decreased
probenecid-sensitive accumulation of the MRP1 substrate cal-
cein and were cross-resistant to doxorubicin and vincristine,
two anticancer drugs well-known to be transported by human
MRP1 [8] ; (iii) the MRP1 gene copy number was augmented
in GLC4/Sb30 cells as assessed by Southern blot analysis and
such a gene ampli¢cation, which certainly accounts for at least
part of the increased MRP1 levels in GLC4/Sb30 cells, is
usually observed for genes encoding resistance markers to-
ward the agent used for selection [20,22] ; and (iv) MK571,
a potent inhibitor of MRP1 known to speci¢cally reverse
MRP1-mediated anticancer drug resistance [12], was also
found to markedly down-modulate resistance of GLC4/Sb30
cells to antimony and to inhibit cellular export of the metal.
In contrast, MK571 only weakly increased the sensitivity to
antimony of parental GLC4 cells and this e¡ect can likely be
attributed to inhibition of the MRP1 constitutively present at
low, but detectable, levels in these cells.
It is noteworthy that the levels of resistance to antimony
(35-fold) displayed by GLC4/Sb30 cells do not correlate with
the decrease (1.7-fold) in metal accumulation occurring in
these resistant cells when compared to their parental counter-
parts. A possible explanation for this discrepancy is that addi-
tional cellular factors unrelated to MRP1, which remain to be
determined, may also participate in a major way in the resist-
ance of GLC4/Sb30 cells. However, it should be kept in mind
that inhibition of MRP1 activity in GLC4/Sb30 cells by
MK571 allowed them to almost fully reverse their resistance.
In addition, similar discordances between the levels of resist-
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Table 2
E¡ect of MK571 on the Sb(III) sensitivity of GLC4/Sb30
IC50 (WM)a
Sb(III) Sb(III)+MK571 (50 WM) P
GLC4 3.2 þ 0.3 1.2 þ 0.3 (2.6)b 0.004
GLC4/Sb30 112.6 þ 11.0 7.1 þ 0.9 (15.8) 6 0.001
aThe IC50s were determined using a MTT assay. Data are the mean þ S.E.M. of four independent experiments. Statistical signi¢cance (P) was
determined by Student’s t-test.
bThe fold sensitization, calculated as the ratio of IC50 in the absence of MK571 to IC50 in the presence of MK571, is shown in parentheses.
Fig. 3. MRP1 activity in GLC4/Sb30 cells. Cells were incubated
with 0.5 WM calcein AM for 1 h at 37‡C in the absence (3) or pres-
ence (+) of 1 mM probenecid. Cellular calcein contents were then
analyzed by spectro£uorimetry as described in Section 2. Each col-
umn is the mean þ S.E.M. of three independent experiments per-
formed in triplicate. *P6 0.05.
L. Vernhet et al./FEBS Letters 443 (1999) 321^325324
ance and those of drug accumulation and e¥ux have already
been reported in various MRP1-overexpressing cell lines [8,9] ;
more strikingly, multidrug-resistant H69AR cells, from which
MRP1 cDNA was originally cloned, did not show any change
in drug accumulation [23]. In these cell lines, alterations of
drug distribution among intracellular compartments have,
however, been reported. MRP1 is therefore thought not
only to act as a plasma drug e¥ux pump, but also to con-
tribute to the sequestration of cytotoxic compounds in some
intracellular compartments, thus resulting in protection of
cellular targets of drugs [9]. Such a mechanism may likely
be operating in GLC4/Sb30 cells and, in addition to MRP1-
mediated cellular metal e¥ux, MRP1-related alteration of cel-
lular metal localization may account for the high levels of
resistance displayed by these cells. Interestingly, the ABC pro-
tein YCF1, which confers heavy metal resistance to yeast and
shares strong structural similarities with MRP1, has recently
been demonstrated to function as a vacuolar pump [24].
In summary, the present study supports the conclusion that
overexpression of the MRP1 export pump constitutes one
major molecular basis of resistance in human heavy metal-
selected cells and furthermore demonstrates that MRP1 over-
expression can occur in response to chronic exposure not only
to anticancer drugs but also to cytotoxic heavy metals.
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